

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number  
**WO 2005/044298 A1**

- (51) International Patent Classification\*: **A61K 39/00**, (74) Agent: MILES, John; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).  
A61P 37/00
- (21) International Application Number: PCT/GB2004/004412
- (22) International Filing Date: 19 October 2004 (19.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 21 October 2003 (21.10.2003) GB 0324523.0
- (71) Applicants (for all designated States except US): MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1B 1AL (GB). ARDANA BIOSCIENCE LIMITED [GB/GB]; 38 Melville Street, Edinburgh EH3 7HA (GB).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): BEST, Simon, Geoffrey [GB/GB]; Ardana Bioscience Limited, 38 Melville Street, Edinburgh EH3 7HA (GB). KELLY, Rodney, William [GB/GB]; MRC Human Reproductive Sciences Unit, The Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB (GB).
- (81) Designated States (unless otherwise indicated, for every kind of regional protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GM, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS OF TREATMENT

(57) Abstract: A method of inducing tolerance to a therapeutic cell in a patient who is to be administered subsequently a therapeutic amount of the said therapeutic cell or a precursor thereof, the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell, or an antigen found thereon or a derivative of said antigen, and (b) an agent which raises the effective cAMP concentration in a monocyte cell. A method of reducing the risk of rejection of a transplant in a patient in need of transplantation of a therapeutic cell for cell or tissue regeneration, the method comprising administering to the patient prior to the transplant (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell which therapeutic cell is, or is able to differentiate into, the cell or tissue to be regenerated, or an antigen found thereon or a derivative of said antigen, and (b) an agent which raises the effective cAMP concentration in a monocyte cell. A method of treating a patient in need of cell or tissue regeneration the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell to be administered subsequently which therapeutic cell is, or is able to differentiate into, the cell or tissue to be regenerated, or an antigen found thereon or a derivative of said antigen, (b) an agent which raises the effective cAMP concentration in a monocyte cell in an amount to induce tolerance to the said therapeutic cell, and subsequently administering to the patient (c) a therapeutic amount of the said therapeutic cell. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is a prostaglandin. Preferably it is used in combination with GM-CSF or a derivative thereof.

WO 2005/044298 A1